How the structural determinants of health inequities impact access to prescription medication for pregnant women in Australia: a narrative review.
Australia
Equity
Financing
Health systems
Maternal health
Pharmaceutical preparations
Policy
Journal
The Lancet regional health. Western Pacific
ISSN: 2666-6065
Titre abrégé: Lancet Reg Health West Pac
Pays: England
ID NLM: 101774968
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
02
07
2023
revised:
06
09
2023
accepted:
21
09
2023
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
Structural factors that contribute to health disparities (e.g., population-level policies, cultural norms) impact the distribution of resources in society and can affect medication accessibility; even in high-income countries like Australia. Industry practices and regulatory approaches (e.g., a conservative approach to testing medicines in pregnant women) influence the availability of safety and efficacy data necessary for the licencing and funding of prescription medications used during pregnancy. Consequently, pregnant women may be prescribed medications outside of regulatory or funder-approved indications, posing risks for both prescribers and pregnant women and potentially compromising equitable access to medications. This review examines the regulatory and legislative structural factors that contribute to health disparities and perpetuate the deeply ingrained social norm that we should be protecting pregnant women Australian Government Research Training Program Stipend from the University of Technology Sydney, National Health and Medical Research Council (NHMRC) Fellowship, Channel 7 Children's Research Foundation Fellowship (CRF-210323).
Identifiants
pubmed: 38357390
doi: 10.1016/j.lanwpc.2023.100934
pii: S2666-6065(23)00252-3
pmc: PMC10865029
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100934Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
E.C. reports grants from Ferring Pharmaceuticals, outside the submitted work; and a role as Vice President of Women's Healthcare Australasia. No other authors have any conflicts of interest to disclose.